News Scoop: Lumos Labs has FDA nod for ADHD DTx Prismira Lumos Labs has secured its first 510(k) clearance for a digital therapeutics offering, paving the way for entrance into the regulated app market.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.